Chemomab therapeutics ltd.CMMB.US Overview

US StockHealthcare

(No presentation for CMMB)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

CMMB Overall Performance

CMMB AI Analysis & Strategy

CMMB Recent Performance

-0.66%

Chemomab therapeutics ltd.

0.81%

Avg of Sector

-1.14%

S&P500

CMMB PowerScanner

CMMB Key Information

CMMB Valuation Metrics

CMMB Earnings Table

CMMB Profile

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.